SPOTLIGHT -
Dr. Antonarakis on the Benefits of Genetic Testing for Select Patients With Prostate Cancer
Emmanuel Antonarakis, MD, discusses the benefits of somatic and germline testing for patients with prostate cancer.
Read More
Dr. Antonarakis on Therapeutic Agents for Select Patients With mCRPC
Emmanuel Antonarakis, MD, discusses the different therapeutic agents that are available for patients with metastatic castration-resistant prostate cancer who display either somatic or germline mutations.
Dr. Antonarakis on Implications of an MMR Deficiency in Prostate Cancer
Emmanuel S. Antonarakis, MD, associate professor of oncology, Johns Hopkins University, discusses the clinical implications of an MMR deficiency in patients with prostate cancer.
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
